Market Closed -
Nasdaq
04:00:00 2024-04-30 pm EDT
5-day change
1st Jan Change
50.02
USD
-2.13%
-8.12%
-9.87%
This article is reserved for members
Not a member ?
Free registration
Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing
Apr. 18
MT
Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing
Apr. 03
MT
Arcellx Insider Sold Shares Worth $35,575,755, According to a Recent SEC Filing
Mar. 25
MT
Arcellx Insider Sold Shares Worth $633,582, According to a Recent SEC Filing
Mar. 19
MT
Needham Raises Arcellx Price Target to $81 From $72, Maintains Buy Rating
Mar. 18
MT
Morgan Stanley Initiates Arcellx With Overweight Rating, $81 Price Target
Mar. 07
MT
Truist Adjusts Price Target on Arcellx to $87 From $57, Maintains Buy Rating
Mar. 05
MT
Barclays Adjusts Arcellx's Price Target to $73 From $62, Keeps Overweight Rating
Feb. 29
MT
Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 28
CI
Earnings Flash (ACLX) ARCELLX Posts Q4 Revenue $63.1M
Feb. 28
MT
Arcellx, Inc. Enters an Assignment of Lease with A Third Party Sublessee
Jan. 31
CI
Arcellx, Inc. Approves Relocation of the Headquarters
Jan. 31
CI
Arcellx Insider Sold Shares Worth $419,926, According to a Recent SEC Filing
Jan. 08
MT
Arcellx Insider Sold Shares Worth $1,606,804, According to a Recent SEC Filing
Jan. 08
MT
Arcellx Insider Sold Shares Worth $470,551, According to a Recent SEC Filing
Jan. 08
MT
Arcellx Insider Sold Shares Worth $6,020,281, According to a Recent SEC Filing
Dec. 19
MT
Scotiabank Starts Arcellx With Sector Outperform Rating, $66 Price Target
Dec. 19
MT
Arcellx Insider Sold Shares Worth $24,774,441, According to a Recent SEC Filing
Dec. 18
MT
Needham Adjusts Price Target on Arcellx to $65 From $60, Keeps Buy Rating
Dec. 11
MT
Arcellx Phase 1 Expansion Study Data for Cancer Candidate Shows 100% Overall Response Rate
Dec. 08
MT
Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash
Dec. 08
CI
HC Wainwright Raises Arcellx's Price Target to $60 From $50, Keeps Buy Rating
Nov. 15
MT
Needham Raises Arcellx Price Target to $60 From $51, Maintains Buy Rating
Nov. 15
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
Nov. 15
MT
Sector Update: Health Care
Nov. 15
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Companyâs lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
More about the company
Last Close Price
51.11
USD
Average target price
80.31
USD
Spread / Average Target
+57.13%
Consensus
1st Jan change
Capi.
-9.87% 2.72B +0.17% 42.86B +10.92% 42.74B +44.30% 41.36B -6.20% 27.68B +5.23% 25.15B -24.79% 18.63B +26.69% 12.37B -3.13% 11.92B +6.57% 11.21B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1